FDA Approves Coronary Use Of Possis Medical's Angiojet System

Possis Medical Inc. (Minneapolis) has received approval from FDA to market its Coronary AngioJet Rheolytic thrombectomy system for the removal of blood clots in symptomatic native coronary arteries and coronary bypass grafts.

According to a statement by Robert Dutcher, Possis Medical president and CEO, the potential worldwide market of the Coronary AngioJet System is estimated to be $800 million.

The AngioJet System is designed to remove blood clots from large- and small-diameter blood vessels throughout the body. The system delivers jets of pressurized saline solution through tiny openings in the tip of a catheter positioned near the blood clot, breaking the clot into tiny particles that are propelled back through the catheter out of the patient's body and into a disposable collection bag.